1. Home
  2. SNGX vs DSS Comparison

SNGX vs DSS Comparison

Compare SNGX & DSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SNGX
  • DSS
  • Stock Information
  • Founded
  • SNGX 1987
  • DSS 1984
  • Country
  • SNGX United States
  • DSS United States
  • Employees
  • SNGX N/A
  • DSS N/A
  • Industry
  • SNGX Biotechnology: Pharmaceutical Preparations
  • DSS Containers/Packaging
  • Sector
  • SNGX Health Care
  • DSS Consumer Discretionary
  • Exchange
  • SNGX Nasdaq
  • DSS Nasdaq
  • Market Cap
  • SNGX 7.4M
  • DSS 7.3M
  • IPO Year
  • SNGX 1987
  • DSS N/A
  • Fundamental
  • Price
  • SNGX $2.39
  • DSS $0.95
  • Analyst Decision
  • SNGX
  • DSS
  • Analyst Count
  • SNGX 0
  • DSS 0
  • Target Price
  • SNGX N/A
  • DSS N/A
  • AVG Volume (30 Days)
  • SNGX 51.7K
  • DSS 19.1K
  • Earning Date
  • SNGX 03-14-2025
  • DSS 03-26-2025
  • Dividend Yield
  • SNGX N/A
  • DSS N/A
  • EPS Growth
  • SNGX N/A
  • DSS N/A
  • EPS
  • SNGX N/A
  • DSS N/A
  • Revenue
  • SNGX $364,183.00
  • DSS $25,019,000.00
  • Revenue This Year
  • SNGX N/A
  • DSS N/A
  • Revenue Next Year
  • SNGX $76.64
  • DSS N/A
  • P/E Ratio
  • SNGX N/A
  • DSS N/A
  • Revenue Growth
  • SNGX N/A
  • DSS N/A
  • 52 Week Low
  • SNGX $1.83
  • DSS $0.77
  • 52 Week High
  • SNGX $14.88
  • DSS $2.30
  • Technical
  • Relative Strength Index (RSI)
  • SNGX 43.83
  • DSS 56.49
  • Support Level
  • SNGX $2.25
  • DSS $0.81
  • Resistance Level
  • SNGX $2.60
  • DSS $0.97
  • Average True Range (ATR)
  • SNGX 0.15
  • DSS 0.07
  • MACD
  • SNGX 0.03
  • DSS 0.01
  • Stochastic Oscillator
  • SNGX 52.27
  • DSS 81.82

About SNGX Soligenix Inc.

Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).

About DSS DSS Inc.

DSS Inc is operating a business focused on Five operating segments Product Packaging, Biotechnology, Commercial Lending, Securities and Investment Management, and Direct Marketing. Currently operates five distinct business lines operate around the globe with primary operations in North America and Asia.

Share on Social Networks: